Evidence map›Paper›PMID 39901690›Full record

ReviewCurrent vascular pharmacology2025

Updates on the Pathogenesis and Therapeutic Approaches for Hereditary Hemorrhagic Telangiectasia.

Alka Yadav, Zahra Shabani, Jasneet Kaur Dhaliwal, Annika Schmidt, Hua Su

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current vascular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alka YadavCenter for Cerebrovascular Research, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7162-7586
Zahra ShabaniCenter for Cerebrovascular Research, University of California, San Francisco, San Francisco, CA, USA.
Jasneet Kaur DhaliwalCenter for Cerebrovascular Research, University of California, San Francisco, San Francisco, CA, USA.
Annika SchmidtCenter for Cerebrovascular Research, University of California, San Francisco, San Francisco, CA, USA.
Hua SuCenter for Cerebrovascular Research, University of California, San Francisco, San Francisco, CA, USA.

Funding

NIH HHS NS027713, NS112819
6 · The paper itself

Abstract

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare and inherited vascular disorder characterized by the development of arteriovenous malformations (AVMs) in various organs and telangiectasia (small AVM) in the mucocutaneous. The majority of HHT patients have haploinsufficiency of genes involved in the transforming growth factor- beta (TGF-β) signaling pathway, including endoglin (

Indexed as

Angiogenesis InhibitorsTelangiectasia, Hereditary HemorrhagicActivin Receptors, Type IIAnimalsArteriovenous MalformationsEndoglinGenetic Predisposition to DiseaseHumansNeovascularization, PathologicPhenotypeSignal TransductionTransforming Growth Factor betaActivin Receptors, Type IIACVRL1 protein, humanAngiogenesis InhibitorsEndoglinENG protein, humanTransforming Growth Factor betaarteriovenous malformationsHereditary hemorrhagic telangiectasiapathogenesistherapeutics.

Identifiers

PMID39901690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.